Leerink Partners initiated coverage on Envista with a new price target
$NVST
Medical/Dental Instruments
Health Care
Leerink Partners initiated coverage of Envista with a rating of Underperform and set a new price target of $19.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/4/2024 | $20.00 | Underperform | Mizuho |
| 10/31/2024 | $16.00 → $23.00 | Underperform → Market Perform | Leerink Partners |
| 10/8/2024 | $20.00 | Equal Weight | Wells Fargo |
| 8/8/2024 | $23.00 → $16.00 | Overweight → Neutral | JP Morgan |
| 4/26/2024 | $33.00 → $21.00 | Overweight → Equal-Weight | Morgan Stanley |
| 2/26/2024 | $19.00 | Underperform | Leerink Partners |
| 2/9/2024 | $30.00 → $23.00 | Buy → Hold | Jefferies |
| 2/8/2024 | Outperform → Mkt Perform | William Blair |
4 - Envista Holdings Corp (0001757073) (Issuer)
4 - Envista Holdings Corp (0001757073) (Issuer)
4 - Envista Holdings Corp (0001757073) (Issuer)
3 - Envista Holdings Corp (0001757073) (Issuer)
3 - Envista Holdings Corp (0001757073) (Issuer)
4 - Envista Holdings Corp (0001757073) (Issuer)
BREA, Calif., Jan. 14, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) ("Envista") will report financial results for its fourth quarter 2024 on Wednesday, February 5, 2025. Envista will discuss these results on a conference call on the same day beginning at 2:00 PM PT and lasting approximately one hour. The call and the accompanying slide presentation will be webcast on the "Investors" section of Envista's website, www.envistaco.com. A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available for one year.
Preliminary unaudited revenue expected to be between $21.0 million and $21.5 million for Q4 2024, and between $79.4 million and $79.9 million for full year 2024 Scott Huennekens Appointed to NeuroPace Board of Directors effective January 6th Management presenting at the 43rd Annual J.P. Morgan Healthcare Conference on January 15th Company to host an Investor Day on January 28th in New York City MOUNTAIN VIEW, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced preliminary unaudited revenue for the quarter and year ended December 31, 20
BREA, Calif., Jan. 7, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) ("Envista") today announced that the company will participate in a presentation at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, from 9:45 – 10:25 am PT at the Westin St. Francis Hotel in San Francisco. There will be an audio-only recording link that can be viewed on Envista's Investor Relations website for up to 30 days following the event. ABOUT ENVISTA HOLDINGS CORPORATION Envista is a global family of more than 30 trusted dental brands, including Nobel Bi
Mizuho initiated coverage of Envista with a rating of Underperform and set a new price target of $20.00
Leerink Partners upgraded Envista from Underperform to Market Perform and set a new price target of $23.00 from $16.00 previously
Wells Fargo initiated coverage of Envista with a rating of Equal Weight and set a new price target of $20.00
BREA, Calif., Jan. 14, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) ("Envista") will report financial results for its fourth quarter 2024 on Wednesday, February 5, 2025. Envista will discuss these results on a conference call on the same day beginning at 2:00 PM PT and lasting approximately one hour. The call and the accompanying slide presentation will be webcast on the "Investors" section of Envista's website, www.envistaco.com. A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available for one year.
BREA, Calif., Oct. 30, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) today announced results for the third quarter of 2024. For the quarter ended September 27, 2024, reported sales were $601.0 million. Core sales in the quarter declined 5.3% over the corresponding quarter in 2023. Net income in the third quarter was $8.2 million or $0.05 per diluted share, compared to net income of $21.5 million or $0.12 per diluted share in Q3 2023. Adjusted net income for the third quarter of 2024 was $21.1 million or $0.12 per diluted share, compared to adjusted net income
BREA, Calif., Oct. 7, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) ("Envista") will report financial results for its third quarter 2024 on Wednesday, October 30, 2024. Envista will discuss these results on a conference call on the same day beginning at 2:00 PM PT and lasting approximately one hour. The call and the accompanying slide presentation will be webcast on the "Investors" section of Envista's website, www.envistaco.com. A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available for one year. Y
8-K - Envista Holdings Corp (0001757073) (Filer)
SCHEDULE 13G - Envista Holdings Corp (0001757073) (Subject)
10-Q - Envista Holdings Corp (0001757073) (Filer)
Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210769572/en/R. Scott Huennekens (Photo: Business Wire) T
WESTPORT, Conn., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE:CODI) ("CODI" or the "Company"), an owner of leading middle market businesses, announced today that Stephen Keller has been appointed as the Company's Chief Financial Officer (CFO), effective August 31, 2024. He will be replacing Ryan Faulkingham, who has served as the Company's CFO since July 2013 and is departing the Company effective August 30, 2024. Mr. Faulkingham will continue to serve in an advisory capacity in order to facilitate a seamless transition. In his new role, Mr. Keller will lead CODI's finance organization, including accounting, planning, treasury, tax, reporting, and investor relations. He b
BREA, Calif., July 15, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) today announced the following key leadership appointments: Eric Hammes joins Envista as Chief Financial OfficerStefan Nilsson joins Envista as President, Nobel BiocareVeronica Acurio joins Envista as President, Ormco"It is a pleasure to welcome this trio of successful leaders to Envista," said Paul Keel, Chief Executive Officer. "Each brings experience in dental along with a proven track record of continuous improvement, leading with purpose, and creating value for all stakeholders. Today's an
SC 13G - Envista Holdings Corp (0001757073) (Subject)
SC 13G/A - Envista Holdings Corp (0001757073) (Subject)
SC 13G - Envista Holdings Corp (0001757073) (Subject)